Member Info for Brighty1

SOG, Citizen and the rest of "Team Sareum", as we know we don't need Motley Fool. The best research - by far - is right here in front of you on this board. You and many others who post here regularly have unearthed some stunning facts and figures over the last few years about Sareum. Thanks. Good luck, Brighty

I think we will need an observer at Cambridge (CBG) Airport in Taversham, just a few miles from the Sareum HQ, looking out for the the private jets flying in CEO’s such as:
Paul Hudson, Chief Executive of Sanofi,
Albert Bourla CEO of Pfizer,
Pascal Soriot ceo of AstraZeneca
Or my favourite for a deal with Sareum, Robert Davis the new CEO of Merck MSD
Or there could be Emma Walmsley ceo of GlaxoSmithKline arriving at the local bus stop.
Keep those eyes peeled….
Good luck, Brighty

Not at all surprised to see this at 9.4p today. The fact that our TYK2 worked in combo with dexamethasone, recently hailed as the lifesaver for over 1 million Covid patients is terrific news. Add that to the recent quote in the RNS from Sareum: "Initial results are encouraging and demonstrate that SDC-1801 reduces the levels of cytokines associated with Acute Respiratory Distress Syndrome in human lung cells infected with SARS-CoV-2" and you can see why so many investors are waking up to the potential of the Sareum science. Good luck all Sareum investors, Brighty

My favourite little chart for those newbies that missed it last year highlighting some of those stunning pharma sector rises that were achieved in 2020. Anything is possible......
NCYT 7p to 1210p in 2020
ODX 7p to 126p in 2020
AVCT 14p – 215p in 2020
SNG 6p to 240p in 2020
HEMO 1p to 15p in 2020
PYC 1.5p to 10.5p in 2020
YGEN 7p- 24p in 2020
N4P 2p to 16p in 2020
VAL 6p to 60p in 2020
If they can do it, then so can Sareum.
We are now on the launch pad at 8p+ to achieve similar meteoric gains in 2021.
Good luck all Sareum shareholders. Brighty

Welcome all new investors. There's immense promise here. A few key points for you:

• Sareum’s worldwide patents are in place...
• Sareum’s two TYK2/JAK1 programmes targeting autoimmune diseases and cancer (SDC 1801&1802) are progressing....
• Sareum’s commercial interest in SRRA 737 CHK1 has been re-negotiated / tidied up ready for a deal…SRA737 Combo trials with WEE1 (AZ), Keytruda (MSD) and Gemcitabine (Lilly) all successful
• Sareum has a potential treatment for Covid-19…. "Initial results are encouraging and demonstrate that SDC-1801 reduces the levels of cytokines associated with Acute Respiratory Distress Syndrome in human lung cells infected with SARS-CoV-2".
Plus in relation to Covid we know that our TYK2 works in combo with dexamethasone, recently hailed as the lifesaver for over 1 million Covid patients.
* News on many fronts due soon.

We all witnessed what happened in our sector in 2020 with the sublime share price rises of NCYT, AVCT, SNG etc. If they can do it, so can Sareum. Patience is all that is required.

Good luck, Brighty

Fantastic upbeat CEO statement:

"This will generate material cashflow to self-fund high return, fast payback investment opportunities and reduce debt - even at low oil prices. The delivery of this business plan required us to address several fundamental aspects of the business and I am proud to report that we have made excellent progress".

A great turn around story evolving under Rahul Dhir's inspired leadership. Looks like 70p soon and then 100p+ by the end of this year.

Good luck, Brighty

Note the wording "Claim and Counter claim".
"As previously announced, N Brown is currently involved in a claim and counterclaim with Allianz Insurance plc.... the value of this additional element of the claim, should its' application be successful, to be up to £36m". Good luck, Brighty

Congrats Basil and Boil B - You got your 7.1p today! Onwards and upwards to your next prediction of 20p by the end of June. Good luck, Brighty

The CEO of TEK was quite clear in his recent LSE interview that he would seek the best avenue to maximise shareholder value when the time came to exit TEK's investments in Guident, Salarius, Lucyd and Belluscura. For those that have a long term investment plan this has huge promise as the recent RNS' and interviews highlight. Another 3 years and this could be 10 or 15 times higher, at least. Good luck, Brighty

Yes absolutely, I've been invested here since the 29p days and based purely on what we know so far £5 per share is my prediction for 2021 with £8 - £10 per share as a takeover price. It's just a shame that the UK Gov't is being so slow on what Synairgen has to offer Covid patients but great news filtering out of the USA. It's clear that we have a drug formulation that has proven to saves lives. Sir Stephen Holgate and Richard Marsden have irrefutably stated via RNS after RNS that Inhaled interferon does save lives. We also know that the data shows that SNG boosts lung defences. In summary, SNG is the perfect treatment for Covid and influenza. All looking good here for both new and existing shareholders. Good luck, Brighty

When you know that in combo trials the Sareum science works with WEE1 (AZ), Keytruda (MSD), Gemcitabine (Lilly) and that Sareum has a potential treatment for Covid-19 then why not invest 2.4million if you have it to spend. Plus in relation to Covid we know that our TYK2 works in combo with dexamethasone, recently hailed as the lifesaver for over 1 million Covid patients. No wonder 6.60p has just been paid. Sareum is the real deal. Good luck, Brighty

Workinpharma and Afham, I totally agree that Merck MSD is a likely fit for Sareum. The 1.2billion figure could be dwarfed with a bidding war too. Importantly, MSD has already witnessed how effective the Sareum science is back in June 2019 with the 100% regression of tumours after 21 days in small cell lung cancer trial. Some of you will also know that late last year MSD acquired OncoImmune for $425million plus milestones and sales royalties in a COVID 19 focussed deal. i.e. Licencing or M&A with MSD as I've said before would not surprise me. Not long to go now. Good luck, Brighty

6.14p currently. A 10% rise a day would be preferable. 20p by the end of the month though is looking promising. Good luck, Brighty

You could be right regarding 7.1p today. Certainly 6p+ looks more than possible given the volume. Remember everyone that:
• Sareum’s worldwide patents are in place...
• Sareum’s two TYK2/JAK1 programmes targeting autoimmune diseases and cancer (SDC 1801&1802) are progressing....
• Sareum’s commercial interest in SRRA 737 CHK1 has been re-negotiated / tidied up ready for a deal…SRA737 Combo trials with WEE1 (AZ), Keytruda (MSD) and Gemcitabine (Lilly) all successful
• Sareum has a potential treatment for Covid-19…. "Initial results are encouraging and demonstrate that SDC-1801 reduces the levels of cytokines associated with Acute Respiratory Distress Syndrome in human lung cells infected with SARS-CoV-2".
Plus in relation to Covid we know that our TYK2 works in combo with dexamethasone, recently hailed as the lifesaver for over 1 million Covid patients.

Patience is all that is required.

Good luck, Brighty

Here we are Workinginpharma. Always happy to oblige with my favourite little chart for those newbies that missed it last year highlighting some of those stunning pharma sector rises that were achieved in 2020. Anything is possible......
NCYT 7p to 1210p in 2020
ODX 7p to 126p in 2020
AVCT 14p – 215p in 2020
SNG 6p to 240p in 2020
HEMO 1p to 15p in 2020
PYC 1.5p to 10.5p in 2020
YGEN 7p- 24p in 2020
N4P 2p to 16p in 2020
VAL 6p to 60p in 2020
If they can do it, then so can Sareum.
We are now on the launch pad at 5p to achieve similar meteoric gains in 2021.
Good luck all Sareum shareholders. Brighty

I agree. It looks like the re-rate back to £1+ is now on with the registration of the AffiDX Lateral Flow Test for the EU. Bodes well for ABDX. Good luck, Brighty

Yes, welcome all new investors. There's immense promise here. A few key points for you:

• Sareum’s worldwide patents are in place...
• Sareum’s two TYK2/JAK1 programmes targeting autoimmune diseases and cancer (SDC 1801&1802) are progressing....
• Sareum’s commercial interest in SRRA 737 CHK1 has been re-negotiated / tidied up ready for a deal…SRA737 Combo trials with WEE1 (AZ), Keytruda (MSD) and Gemcitabine (Lilly) all successful
• Sareum has a potential treatment for Covid-19…. "Initial results are encouraging and demonstrate that SDC-1801 reduces the levels of cytokines associated with Acute Respiratory Distress Syndrome in human lung cells infected with SARS-CoV-2".
Plus in relation to Covid we know that our TYK2 works in combo with dexamethasone, recently hailed as the lifesaver for over 1 million Covid patients.
* News on many fronts due soon.

We all witnessed what happened in our sector in 2020 with the sublime share price rises of NCYT, AVCT, SNG etc. If they can do it, so can Sareum. Patience is all that is required.

Good luck, Brighty

For those interested in a takeover price - and why the value of Sareum could multiply very significantly indeed - a good starting point would be Kymab, co-founded by Sareum NED Dr.Owen, which was sold for 1.45 billion to Sanofi in January of this year. Good luck, Brighty

Don't forget that data highlighted that our TYK2 worked in combo with dexamethasone, recently hailed as the lifesaver for over 1 million Covid patients. Add that to the recent quote in the RNS from Sareum: "Initial results are encouraging and demonstrate that SDC-1801 reduces the levels of cytokines associated with Acute Respiratory Distress Syndrome in human lung cells infected with SARS-CoV-2" and you can see why investors are waking up to the potential of the Sareum science. Good luck all Sareum investors, Brighty

A quick reminder....
NCYT 7p to 1210p in 2020
ODX 7p to 126p in 2020
AVCT 14p – 215p in 2020
SNG 6p to 240p in 2020
HEMO 1p to 15p in 2020
PYC 1.5p to 10.5p in 2020
YGEN 7p- 24p in 2020
N4P 2p to 16p in 2020
VAL 6p to 60p in 2020
Given the right newsflow Sareum can achieve similar meteoric gains in 2021. Anything is possible......
Good luck all Sareum shareholders. Brighty